Pfizer (PFE) Long-Term Debt Issuances (2009 - 2025)

Pfizer (PFE) reported Long-Term Debt Issuances of $6.0 billion for Q4 2025, up 500.9% quarter-over-quarter from $997.0 million in Q4 2021.

Pfizer (PFE) Long-Term Debt Issuances (2009 - 2025) Analysis & Trends

Pfizer (PFE) has 12 years of Long-Term Debt Issuances data on file, last reported at $6.0 billion in Q4 2025.

Long-Term Debt Issuances for Q4 2025 came in at $6.0 billion, changed N/A year-over-year; the trailing twelve-month figure through Dec 2025 was $6.0 billion (changed N/A YoY), and the FY2025 annual result was $9.7 billion, changed N/A from the prior year.
Long-Term Debt Issuances advanced to $6.0 billion in Q4 2025 per PFE's latest filing, from $997.0 million in the prior quarter.
Over five years, Long-Term Debt Issuances peaked at $6.0 billion in Q4 2025 and troughed at $997.0 million in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Long-Term Debt Issuances (Qtr)
1	Gsk	93,699,046.73 Bn	93,699,041.77 Bn	7.76 Bn	-
2	Eli Lilly	1,012.06 Bn	1,006.77 Bn	16.22 Bn	-
3	Johnson & Johnson	560.67 Bn	538.62 Bn	15.96 Bn	-
4	AbbVie	402.20 Bn	392.85 Bn	10.78 Bn	7.99 Bn
5	Merck	298.59 Bn	292.94 Bn	12.09 Bn	-
6	Amgen	188.77 Bn	176.74 Bn	5.87 Bn	3.96 Bn
7	Gilead Sciences	160.22 Bn	152.49 Bn	5.52 Bn	-
8	Pfizer	148.19 Bn	135.42 Bn	-1.21 Bn	-
9	Bristol Myers Squibb	116.72 Bn	106.26 Bn	8.07 Bn	-
10	Novartis Ag	109.78 Bn	109.09 Bn	-	-

Download Data